Evidence map›Paper›PMID 30121842›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2018

Expression level of NUAK1 in human nasopharyngeal carcinoma and its prognostic significance.

Jiaoyang Liu, Guoyan Tang, He Huang, Huan Li, Peng Zhang, Lihua Xu

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. The Role of hsa-miR-21 and Its Target Genes Involved in Nasopharyngeal Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. LncRNACancer management and research · 2020
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiaoyang LiuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Guangzhou, 510230, Guangdong, China.ORCID http://orcid.org/0000-0002-0456-663X
Guoyan TangDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Guangzhou, 510230, Guangdong, China.
He HuangGeneral Surgery Department, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Huan LiBreast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Peng ZhangBreast Cancer Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Lihua XuDepartment of Hematology, The First Affiliated Hospital of Guangzhou Medical University, No. 1 Kangda Road, Guangzhou, 510230, Guangdong, China. xlhua@gzhmu.edu.cn.
First Affiliated Hospital of Guangzhou Medical University · CNSun Yat-sen University · CN

Funding

The Guangdong Province Natural Science Foundation 2015A030310126The National Natural Science Foundation of China 81672661
6 · The paper itself

Abstract

backgroundNasopharyngeal carcinoma (NPC) is notable for its high incidence rates in select geographic and ethnic populations, especially among Chinese and Malay populations in Southeastern Asia. However, relevant biomarkers for the development and prognosis of NPC are not yet clear; therefore, discovering novel biomarkers will facilitate prediction of prognosis and development of targeted therapeutic tactics. This study aims to quest the potential prognostic value of NUAK1 (a downstream member of Akt) in NPC.

methodsImmunohistochemistry was performed to measure the expression of NUAK1 in paraffin-embedded NPC samples. Statistical analysis, encompassing chi-square tests and Student's t test, was also employed to evaluate the association between the expression of NUAK1 and clinicopathologic features. In addition, the survival analysis was used to detect the prognostic significance of NUAK1 in NPC.

resultsExcessive expression of NUAK1 was found in NPC tissues at mRNA levels. Statistical analysis revealed a correlation of NUAK1 expression with maximum neck lymph node diameter (p = 0.025) and WHO histological type (p = 0.021). Furthermore, according to survival analysis, there was clinical relevance between the upregulation of NUAK1 in NPC and DFS. Subgroup analysis indicated that the expression of NUAK1 was strongly associated with DFS (p = 0.027) and OS (p = 0.026) duration in the patients of N1-3 tumors, but not in patients with N0 tumors. The expression of NUAK1 was also strongly associated with OS (p = 0.044) and DFS (p = 0.007) in patients of late stage tumour (UICC3-5), but not in patients of early stage tumour (UICC1-2). In addition, COX regression illustrated that N classification and NUAK1 expression were independent prognostic factors for disease-free survival.

conclusionOur study postulated that NUAK1 is excessively expressed in NPC and may serve as a potential predictor of prognosis for NPC.

Indexed as

Gene Expression Regulation, NeoplasticUp-RegulationAdultAgedBiomarkers, TumorBiopsyCarcinomaFemaleHumansImmunohistochemistryMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm StagingPrognosisBiomarkers, TumorNUAK1 protein, humanProtein KinasesRepressor ProteinsRNA, NeoplasmNasopharyngeal carcinomaNUAK1Prognosis

Identifiers

PMID30121842
OpenAlexW2886483881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.